Crazy 8 Initiative Grant Program on Pediatric Brain Tumors
Descriptions
Opportunity link:
Opportunity type:
Sponsor:
Award amount and duration:
Currency:
Eligibility
• PIs, Co-PIs, and Co-Is must have an MD, PhD, or MD/PhD or equivalent and be appointed as faculty (or equivalent) at an academic institution
• PIs, Co-PIs, and Co-Is must have a track record of publication and funding productivity that demonstrates that the project can be accomplished by the investigators
• PIs, Co-PIs, and Co-Is' institutions may be based in the United States or abroad, and applicants need not be United States citizens. Funds must be granted to nonprofit institutions or organizations and will be distributed in US dollars
• PIs, Co-PIs may not have been PIs or Co-PIs on a previously funded Crazy 8 Project
• Co-Is may not be on a currently funded Crazy 8 Project at the time of submission. However, if a Co-I with special expertise is needed that is already on a team, please send your request with a brief description of why this member is critical for the team to Margaret Poore before the submission deadline at M.Poore@AlexsLemonade.org and we will review it administratively
Summary
This ALSF Crazy 8 RFA focuses on developing and enhancing pediatric brain tumor treatments. The focus must be on pediatric/adolescent brain tumors and should be a consortium of two or more institutions with different areas of research collaborating to integrate their expertise. It is strongly encouraged to have a patient advocate on the team. The proposals will be judged on innovation, scientific soundness, significance, and the potential impact on improving the lives of children with cancer. The award selection process involves three stages: (1) a letter of intent to narrow the pool to the projects most in line with the scope of the Crazy 8 Initiative; (2) a full proposal to select finalists; and (3) a virtual presentation to ALSF leadership and the Crazy 8 Scientific Advisory Board to choose the award recipient(s).
The LOI deadline has passed. Those who have been invited to submit a full proposal can review the full application guidelines at this LINK.
Overhead
ALSF will pay up to 10% in indirect costs; if the applicant elects to request indirect costs, the total budget including indirect costs may not exceed the range of $3-5 million USD. The 10% indirect costs should be assessed on the Total Direct Costs. Indirect costs may be assessed on subawards’ Total Direct Costs but must be excluded from the primary institution’s Total Direct Costs for calculating indirect.
Deadlines
Application deadlines
RSO detailed review deadline
RSO final internal review deadline
Program application deadline
Approvals
NOTE: Consult your Faculty Associate Dean (Research) (ADR) regarding Faculty-specific deadlines and submission processes.
Principal Investigators: Complete a Research Management System (RMS) record, including a copy of your complete application, and submit this for approvals in RMS.
Postdocs, students, and trainees: For fellowships and externally-sponsored research training awards or opportunities, you must complete the Research Funding Application Approval (RFAA) Trainee PDF form, and submit it, along with a complete copy of the application, to Research Services at rsotrainee@ucalgary.ca. Trainees should not use RMS at this time.
Approvals: The University of Calgary requires that all funding applications be approved prior to submission. Approval requires signatures via either RMS or the RFAA Trainee form, in the following order:
- Principal Investigator
- Department Head
- Faculty ADR/Dean
- Research Services (on behalf of the Vice-President Research)
Read the Meaning of Grant Signatures policy to understand what your approval means. Please see the agency guidelines for details about which signatures are required on your application, as it may differ from internal requirements.
Late submissions: Late submissions will only be accepted in cases of medical or family emergencies, or other exceptional circumstances. If you submit your RMS record to Research Services after the internal deadline has passed, you must secure additional approvals. Please read: Late Applications Process.
Additional Information
RESOURCES
Reminder: The sooner the researcher engages with Research Services, the more help we can be!
Contact the following Research Service units for support with:
Projects Involving Indigenous Research:
Support with incorporating wise practices in Indigenous research, community engagement, and Indigenous data management is available through the Indigenous Research Support Team (IRST).
Applicants can reach out by email to IRST at IRST@ucalgary.ca in advance of the RSO internal deadline. For more information about IRST, please visit the IRST webpage.
Knowledge Mobilization, Research Impact Assessment, DORA:
Support for knowledge mobilization/engagement/translation, community partnerships, research impact, responsible research assessment (DORA), and open science, is available through the Knowledge to Impact team.
Applicants can reach out by email to the KI team at knowledge.impact@ucalgary.ca.
For more information and access to resource archives, please visit the KI team webpage.
Research Data Management:
For information on research data management plans, processes, or best practices for your research program, please contact research.data@ucalgary.ca.
EDI in Research:
RSO can provide resources and support to research teams on the integration of equitable and inclusive practices in research design and research practice.
Contact edi.rso@ucalgary.ca for more information.
Research Security:
The Research Security Division is available to ensure researchers adhere to research security guidelines and policies, including the National Security Guidelines for Research Partnerships (NSGRP) and the policy on Sensitive Technology Research and Affiliations of Concern (STRAC).
Visit the Research Security website to learn more or contact researchsecurity@ucalgary.ca.
Pre-Award Submissions:
RMS: Creating a Pre-Award Application
Contact Details
Keywords
Blood–brain barrier
Preclinical models
pediatric oncology